Silverfin false false 31/05/2025 09/12/2023 31/05/2025 Dr Y F A Haba 09/12/2023 M M C Nahab 09/12/2023 19 August 2025 The company was incorporated on 9th December 2023 and started trading on the same date. 15339300 2025-05-31 15339300 bus:Director1 2025-05-31 15339300 bus:Director2 2025-05-31 15339300 core:CurrentFinancialInstruments 2025-05-31 15339300 core:ShareCapital 2025-05-31 15339300 core:RetainedEarningsAccumulatedLosses 2025-05-31 15339300 core:PatentsTrademarksLicencesConcessionsSimilar 2023-12-08 15339300 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2023-12-08 15339300 2023-12-08 15339300 core:PatentsTrademarksLicencesConcessionsSimilar 2025-05-31 15339300 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2025-05-31 15339300 bus:OrdinaryShareClass1 2025-05-31 15339300 2023-12-09 2025-05-31 15339300 bus:FilletedAccounts 2023-12-09 2025-05-31 15339300 bus:SmallEntities 2023-12-09 2025-05-31 15339300 bus:AuditExemptWithAccountantsReport 2023-12-09 2025-05-31 15339300 bus:PrivateLimitedCompanyLtd 2023-12-09 2025-05-31 15339300 bus:Director1 2023-12-09 2025-05-31 15339300 bus:Director2 2023-12-09 2025-05-31 15339300 1 2023-12-09 2025-05-31 15339300 core:PatentsTrademarksLicencesConcessionsSimilar core:TopRangeValue 2023-12-09 2025-05-31 15339300 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill core:TopRangeValue 2023-12-09 2025-05-31 15339300 core:PatentsTrademarksLicencesConcessionsSimilar 2023-12-09 2025-05-31 15339300 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2023-12-09 2025-05-31 15339300 bus:OrdinaryShareClass1 2023-12-09 2025-05-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 15339300 (England and Wales)

TECHNICA PHARMACEUTICALS LIMITED
(Formerly Atlantic Technica Properties UK Limited)

Unaudited Financial Statements
For the financial period from 09 December 2023 to 31 May 2025
Pages for filing with the registrar

TECHNICA PHARMACEUTICALS LIMITED

Unaudited Financial Statements

For the financial period from 09 December 2023 to 31 May 2025

Contents

TECHNICA PHARMACEUTICALS LIMITED

BALANCE SHEET

As at 31 May 2025
TECHNICA PHARMACEUTICALS LIMITED

BALANCE SHEET (continued)

As at 31 May 2025
Note 31.05.2025
£
Fixed assets
Intangible assets 3 66,775
66,775
Current assets
Debtors 4 3,534
Cash at bank and in hand 91,240
94,774
Creditors: amounts falling due within one year 5 ( 107,215)
Net current liabilities (12,441)
Total assets less current liabilities 54,334
Net assets 54,334
Capital and reserves
Called-up share capital 6 100
Profit and loss account 54,234
Total shareholders' funds 54,334

For the financial period ending 31 May 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Technica Pharmaceuticals Limited (registered number: 15339300) were approved and authorised for issue by the Board of Directors on 19 August 2025. They were signed on its behalf by:

M M C Nahab
Director
TECHNICA PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 09 December 2023 to 31 May 2025
TECHNICA PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 09 December 2023 to 31 May 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Technica Pharmaceuticals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Boldrewood Farm, Lenham, Maidstone, Kent, England, ME17 2LT, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Statement of Comprehensive Income in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Trademarks, patents and licences 10 years straight line
Website costs 4 years straight line
Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Employees

Period from
09.12.2023 to
31.05.2025
Number
Monthly average number of persons employed by the Company during the period, including directors 2

3. Intangible assets

Trademarks, patents
and licences
Website costs Total
£ £ £
Cost
At 09 December 2023 0 0 0
Additions 73,193 1,201 74,394
At 31 May 2025 73,193 1,201 74,394
Accumulated amortisation
At 09 December 2023 0 0 0
Charge for the financial period 7,319 300 7,619
At 31 May 2025 7,319 300 7,619
Net book value
At 31 May 2025 65,874 901 66,775

4. Debtors

31.05.2025
£
Amounts owed by Group undertakings 3,131
Amounts owed by directors 100
VAT recoverable 303
3,534

5. Creditors: amounts falling due within one year

31.05.2025
£
Trade creditors 74,890
Corporation tax 16,717
Other creditors 15,608
107,215

6. Called-up share capital

31.05.2025
£
Allotted, called-up and fully-paid
100 Ordinary shares of £ 1.00 each 100

On incorporation, 100 ordinary shares of £1 each were issued and paid at par.